EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hydroxyurea Bridging Before Frontline Tyrosine Kinase Inhibitor Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Critical Appraisal

Mohammed Abdulgayoom, Awni Alshurafa, Abdulrahman F Al-Mashdali, Shehab F Mohamed, Mohamed A Yassin

Oncology · 09.07.2026 · 1-7

DOI: 10.1159/000553465 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology, online erschienen am 09.07.2026. Verfasst von Mohammed Abdulgayoom und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Hydroxyurea-based cytoreduction before tyrosine kinase inhibitor (TKI) initiation remains common in newly diagnosed chronic-phase chronic myeloid leukemia (CML), yet its contemporary value is uncertain. Summary: This critical narrative review examines the historical rationale, biologic basis, clinical evidence, and guideline positions relevant to hydroxyurea use before or immediately around frontline TKI therapy. Hydroxyurea can lower leukocyte and platelet counts rapidly and may provide short-term symptomatic relief while diagnostic confirmation is pending or when definitive treatment access is briefly delayed. However, contemporary evidence does not support routine pretreatment in clinically stable chronic-phase CML. Observational studies have shown no improvement in European LeukemiaNet response milestones, no acceleration of molecular response kinetics, and possible disadvantages including delayed TKI initiation, greater hematologic toxicity, and more treatment interruptions. Randomized studies evaluating early hydroxyurea together with imatinib likewise have not demonstrated meaningful molecular or hematologic benefit over TKI therapy alone. Current guidelines consistently position hydroxyurea as a selective, time-limited bridging option rather than a standard pretreatment strategy. Key Messages: In modern practice, the priority should be rapid initiation of definitive BCR::ABL1-directed therapy once the diagnosis is confirmed and access is secured. Hydroxyurea retains a limited role in selected situations such as symptomatic proliferative burden, suspected leukostasis, clinically important thrombocytosis, or short unavoidable logistical delay to TKI initiation.

Schlagwörter

Stichwörter der Autor:innen

Chronic myeloid leukemiaCytoreductionHydroxyureaLeukostasisTyrosine kinase inhibitor

Autor:innen und Institutionen

  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa.
  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.

Zitieren

APA

Abdulgayoom, M., Alshurafa, A., Al-Mashdali, A. F., F Mohamed, S., & Yassin, M. A. (2026). Hydroxyurea Bridging Before Frontline Tyrosine Kinase Inhibitor Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Critical Appraisal. Oncology, 1-7. https://doi.org/10.1159/000553465

Vancouver

Abdulgayoom M, Alshurafa A, Al-Mashdali AF, F Mohamed S, Yassin MA. Hydroxyurea Bridging Before Frontline Tyrosine Kinase Inhibitor Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Critical Appraisal. Oncology. 2026:1-7. doi:10.1159/000553465

BibTeX
@article{Abdulgayoom2026,
  author = {Abdulgayoom, Mohammed and Alshurafa, Awni and Al-Mashdali, Abdulrahman F and F Mohamed, Shehab and Yassin, Mohamed A},
  title = {Hydroxyurea Bridging Before Frontline Tyrosine Kinase Inhibitor Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Critical Appraisal},
  journal = {Oncology},
  year = {2026},
  pages = {1--7},
  doi = {10.1159/000553465}
}
Kostenlos starten →